NEW YORK – Bio-Techne said this week that it has formed a joint venture company with Fresenius Kabi and Wilson Wolf to provide dedicated support to researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. Each joint venture partner is contributing products and expertise to the new venture.
The companies have been working independently to develop technology that helps advance the manufacturing efficiency of cell and gene therapies, Bio-Techne said.
Wilson Wolf’s G-Rex technology has been designed as a scalable platform for generation of personalized cell therapies. Bio-Techne’s range of proteins, reagents, media, and gene-editing technologies have been designed to activate, reprogram, and stimulate cell growth. Fresenius Kabi’s Lovo cell processing system washes, concentrates, and harvests cells at a scale needed to develop and commercialize cell and gene therapies.
PerkinElmer said this week that its board of directors has declared a regular quarterly dividend of $.07 per share of common stock, payable on May 8 to shareholders of record at the close of business on April 17.
LCM Genect recently announced a distribution deal covering Exosomics’ SelectEV-DNA and SortEV-RNA kits in Italy. The SelectEV-DNA kit is used for extracting DNA and leverages peptide-based technologies, while the SortEV-RNA kit is used for extracting RNA and leverages antibody-based technologies. The kits are designed to aid the selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum. Financial and other terms of the deal were not disclosed.
Sectra said this week it has signed a seven-year contract with Duch hospital Zuyderland Medical Center for Sectra’s digital pathology solution. The solution will be integrated with Zuyderland’s lab information system, providing pathologists with a complete overview of patient’s history. The solution is vendor-neutral and will handle about 35,000 examinations each year, Linköping, Sweden-based Sectra said.
Oncimmune Holdings said this week that it has been included in a consortium established by the Oxford Centre for Early Cancer Detection to aid in the research of earlier detection of hepatocellular carcinoma. The program aims to understand more about changes in the liver as hepatocellular carcinoma develops and to use the information to inform new and more sensitive diagnostic tests that could detect liver cancer earlier.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.